Login to Your Account

Pharma: Clinic Roundup

Thursday, September 13, 2012
• Boehringer Ingelheim GmbH, of Ingelheim, Germany, reported findings at the Asia Pacific Stroke Conference in Tokyo, confirming that, in Asian populations, Pradaxa (dabigatran etexilate) offered considerable benefits for the management of patients with atrial fibrillation.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription